Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Generics Bulletin Podcast: Teva, Sandoz, Sawai and US Orange Book patents

Editorial Team Discusses Strategic Moves By Major Players And US Patent Listing Debate

Executive Summary

Generics Bulletin’s editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA’s Orange Book.

This edition of the Generics Bulletin podcast sees editor Dave Wallace, deputy editor Dean Rudge and reporters Urtė Fultinavičiūtė and Adam Zamecnik discuss recent strategic moves for Teva, Sandoz and Sawai as well as controversy over US patent listings in the US Food and Drug Administration’s Orange Book.

Generics Bulletin previously covered the latest developments in Teva’s strategy in an in-depth article. (Also see "A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets" - Generics Bulletin, 13 May, 2024.)

We also previously covered Sandoz’s most recent strategic moves in biosimilars. (Also see "Sandoz ‘Surfs The Biosimilars Wave’ Despite US Natalizumab Delay" - Generics Bulletin, 8 May, 2024.)

Sawai recently reported its annual results for its financial year ended 31 March. (Also see "Sawai Narrowly Misses Annual Sales Forecast For 2023" - Generics Bulletin, 21 May, 2024.)

And a recent study shed light on US patents filed after FDA approval. (Also see "Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds" - Generics Bulletin, 16 May, 2024.)

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts